SCHEMBL30592500

SCHEMBL30592500

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(CP(=O)(OCc2ccccc2)OC2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)OCc2ccccc2)[C@@H](O)[C@H]1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 5/20 0.59
P2RY2 P41231 4/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
SRC P12931 2/20 0.59
ADORA1 P30542 2/20 0.59
TRPM2 O94759 2/20 0.59
TAS1R3 Q7RTX0 2/20 0.59
TAS1R1 Q7RTX1 2/20 0.59
P2RY11 Q96G91 2/20 0.59
DNPH1 O43598 1/20 0.59
PRKAB2 O43741 1/20 0.59
LDHA P00338 1/20 0.59
ADRB2 P07550 1/20 0.59
FBP1 P09467 1/20 0.59
PRKAG1 P54619 1/20 0.59
PRKAA2 P54646 1/20 0.59
PDE4D Q08499 1/20 0.59
KCNH2 Q12809 1/20 0.59
PRKAA1 Q13131 1/20 0.59
PDE3A Q14432 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26937428 1.00 P2RY1 (0.59) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL26361381 1.00 P2RY1 (0.59) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL30592488 0.90 P2RY1 (0.54) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL26361450 0.90 P2RY1 (0.54) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL23922239 0.88 P2RY1 (0.64) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL22393104 0.88 ENPP1 (0.72) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL22402627 0.87 ENPP1 (0.71) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL23922227 0.87 ENPP1 (0.71) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL109340 0.84 P2RY1 (0.72) P2RY1P2RY2SMN1; SMN2SRCADORA1
SCHEMBL22392944 0.82 ENPP1 (0.76) P2RY1P2RY2SMN1; SMN2SRCADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) 2024-04-18 US disclosed
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 US disclosed
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SMN1; SMN2 4056/4885
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SMN1; SMN2 4056/4885
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RY1 561/4885P2RY2 796/4885SMN1; SMN2 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.